Siemens J, Zhou S, Piskorowski R, Nikai T, Lumpkin EA, Basbaum AI, King D, Julius D
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Examples of Successful Protein Expression with SUMO Reference Protein Type Family Kda System (Pubmed ID)
Examples of Successful Protein Expression with SUMO Reference Protein Type Family kDa System (PubMed ID) 23 (FGF23), human Growth factor FGF superfamily ~26 E. coli 22249723 SARS coronavirus (SARS-CoV) membrane 3C-like (3CL) protease Viral membrane protein protein 33.8 E. coli 16211506 5′nucleotidase-related apyrase (5′Nuc) Saliva protein (apyrase) 5′nucleotidase-related proteins 65 E. coli 20351782 Acetyl-CoA carboxylase 1 (ACC1) Cytosolic enzyme Family of five biotin-dependent carboxylases ~7 E. coli 22123817 Acetyl-CoA carboxylase 2 (ACC2) BCCP domain Cytosolic enzyme Family of five biotin-dependent carboxylases ~7 E. coli 22123817 Actinohivin (AH) Lectin Anti-HIV lectin of CBM family 13 12.5 E. coli DTIC Allium sativum leaf agglutinin (ASAL) Sugar-binding protein Mannose-binding lectins 25 E. coli 20100526 Extracellular matrix Anosmin protein Marix protein 100 Mammalian 22898776 Antibacterial peptide CM4 (ABP-CM4) Antibacterial peptide Cecropin family of antimicrobial peptides 3.8 E. coli 19582446 peptide from centipede venoms of Scolopendra Antimicrobial peptide scolopin 1 (AMP-scolopin 1) small cationic peptide subspinipes mutilans 2.6 E. coli 24145284 Antitumor-analgesic Antitumor-analgesic peptide (AGAP) peptide Multifunction scorpion peptide 7 E. coli 20945481 Anti-VEGF165 single-chain variable fragment (scFv) Antibody Small antibody-engineered antibody 30 E. coli 18795288 APRIL TNF receptor ligand tumor necrosis factor (TNF) ligand 16 E. coli 24412409 APRIL (A proliferation-inducing ligand, also named TALL- Type II transmembrane 2, TRDL-1 and TNFSF-13a) protein Tumor necrosis factor (TNF) family 27.51 E. coli 22387304 Aprotinin/Basic pancreatic trypsin inhibitor (BPTI) Inhibitor Kunitz-type inhibitor 6.5 E. -
Animal Venom Derived Toxins Are Novel Analgesics for Treatment Of
Short Communication iMedPub Journals 2018 www.imedpub.com Journal of Molecular Sciences Vol.2 No.1:6 Animal Venom Derived Toxins are Novel Upadhyay RK* Analgesics for Treatment of Arthritis Department of Zoology, DDU Gorakhpur University, Gorakhpur, UP, India Abstract *Corresponding authors: Ravi Kant Upadhyay Present review article explains use of animal venom derived toxins as analgesics of the treatment of chronic pain and inflammation occurs in arthritis. It is a [email protected] progressive degenerative joint disease that put major impact on joint function and quality of life. Patients face prolonged inappropriate inflammatory responses and bone erosion. Longer persistent chronic pain is a complex and debilitating Department of Zoology, DDU Gorakhpur condition associated with a large personal, mental, physical and socioeconomic University, Gorakhpur, UttarPradesh, India. burden. However, for mitigation of inflammation and sever pain in joints synthetic analgesics are used to provide quick relief from pain but they impose many long Tel: 9838448495 term side effects. Venom toxins showed high affinity to voltage gated channels, and pain receptors. These are strong inhibitors of ion channels which enable them as potential therapeutic agents for the treatment of pain. Present article Citation: Upadhyay RK (2018) Animal Venom emphasizes development of a new class of analgesic agents in form of venom Derived Toxins are Novel Analgesics for derived toxins for the treatment of arthritis. Treatment of Arthritis. J Mol Sci. Vol.2 No.1:6 Keywords: Analgesics; Venom toxins; Ion channels; Channel inhibitors; Pain; Inflammation Received: February 04, 2018; Accepted: March 12, 2018; Published: March 19, 2018 Introduction such as the back, spine, and pelvis. -
Psalmopoeus Cambridgei (Trinidad Chevron Tarantula)
UWI The Online Guide to the Animals of Trinidad and Tobago Ecology Psalmopoeus cambridgei (Trinidad Chevron Tarantula) Order: Araneae (Spiders) Class: Arachnida (Spiders and Scorpions) Phylum: Arthropoda (Arthropods) Fig. 1. Trinidad chevron tarantula, Psalmopoeus cambridgei. [http://www.exoreptiles.com/my/index.php?main_page=product_info&products_id=1127, downloaded 30 April 2015] TRAITS. A large spider, maximum size 11-14cm across the legs, with chevrons (V-shaped marks) on the abdomen (Fig. 1). Males are either grey or brown in colour, and females vary from green to brown with red or orange markings on the legs (Wikipedia, 2013). The Trinidad chevron tarantula is hairy in appearance, has eight legs, and its body is divided into two parts, the cephalothorax and the abdomen which are connected by a pedicel that looks like a narrow stalk (Fig. 2). The cephalothorax has eight legs plus a pair of smaller leg-like appendages (pedipalps) used to catch prey; in males these have palpal bulbs attached to the ends for holding sperm (Fig. 3). The mouth has chelicerae with fangs at the ends and swollen bases that house the venom glands, and there are eight small eyes (Foelix, 2010). However, even with eight eyes the Trinidad chevron tarantula can hardly see and so depends mostly on touch, smell, and taste to find its way. There are organs on their feet to detect changes in the environment and special type of hair on their legs and pedipalps for taste. The second part, the abdomen attached to a narrow waist, can UWI The Online Guide to the Animals of Trinidad and Tobago Ecology expand and contract to accommodate food and eggs; two pairs of spinnerets are located at the end of the abdomen (Fig. -
A Functional Nav1.7-Navab Chimera with a Reconstituted High-Affinity Protx-II Binding Site S
Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/06/23/mol.117.108712.DC1 1521-0111/92/3/310–317$25.00 https://doi.org/10.1124/mol.117.108712 MOLECULAR PHARMACOLOGY Mol Pharmacol 92:310–317, September 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics A Functional NaV1.7-NaVAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site s Ramkumar Rajamani, Sophie Wu, Iyoncy Rodrigo, Mian Gao, Simon Low, Lisa Megson, David Wensel, Rick L. Pieschl, Debra J. Post-Munson, John Watson, David R. Langley, Michael K. Ahlijanian, Linda J. Bristow, and James Herrington Molecular Discovery Technologies, Wallingford, Connecticut, Princeton, New Jersey, and Waltham, Massachusetts (R.R., S.W., I.R., M.G., S.L., L.M., D.W., D.R.L.); Discovery Biology (R.L.P., D.J.P.-M., M.K.A., L.J.B., J.H.) and Lead Discovery and Optimization (J.W.), Bristol-Myers Squibb Company, Wallingford, Connecticut Downloaded from Received March 6, 2017; accepted June 14, 2017 ABSTRACT The NaV1.7 voltage-gated sodium channel is implicated in part of the voltage sensor domain 2 (VSD2) of NaV1.7. Importantly, human pain perception by genetics. Rare gain of function this chimera, DII S1–S4, forms functional sodium channels and is molpharm.aspetjournals.org mutations in NaV1.7 lead to spontaneous pain in humans whereas potently inhibited by the NaV1.7 VSD2 targeted peptide toxin loss of function mutations results in congenital insensitivity to pain. ProTx-II. Further, we show by [125I]ProTx-II binding and surface Hence, agents that specifically modulate the function of NaV1.7 plasmon resonance that the purified DII S1–S4 protein retains high have the potential to yield novel therapeutics to treat pain. -
Potent Neuroprotection After Stroke Afforded by a Double-Knot Spider-Venom Peptide That Inhibits Acid-Sensing Ion Channel 1A
Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a Irène R. Chassagnona, Claudia A. McCarthyb,c, Yanni K.-Y. China, Sandy S. Pinedaa, Angelo Keramidasd, Mehdi Moblie, Vi Phamb,c, T. Michael De Silvab,c, Joseph W. Lynchd, Robert E. Widdopb,c, Lachlan D. Rasha,f,1, and Glenn F. Kinga,1 aInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia; bBiomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; cDepartment of Pharmacology, Monash University, Clayton, VIC 3800, Australia; dQueensland Brain Institute, The University of Queensland, St. Lucia, QLD 4072, Australia; eCentre for Advanced Imaging, The University of Queensland, St. Lucia, QLD 4072, Australia; and fSchool of Biomedical Sciences, The University of Queensland, St. Lucia, QLD 4072, Australia Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved February 6, 2017 (received for review September 1, 2016) Stroke is the second-leading cause of death worldwide, yet there are extracellular pH that occurs during cerebral ischemia. ASIC1a is the no drugs available to protect the brain from stroke-induced neuronal primary acid sensor in mammalian brain (9, 10) and a key mediator of injury. Acid-sensing ion channel 1a (ASIC1a) is the primary acid sensor stroke-induced neuronal damage. Genetic ablation of ASIC1a reduces in mammalian brain and a key mediator of acidosis-induced neuronal infarct size by ∼60% after transient middle cerebral artery occlusion damage following cerebral ischemia. Genetic ablation and selective (MCAO) in mice (7), whereas pharmacologic blockade with modestly pharmacologic inhibition of ASIC1a reduces neuronal death follow- potent ASIC1a inhibitors, such as amiloride (7) and nonsteroidal anti- ing ischemic stroke in rodents. -
Vol. 9(1), 2016 ISSN 1675 – 5650
Vol. 9(1), 2016 ISSN 1675 – 5650 MALAYSIAN COCOA JOURNAL ------------------------------------------------------------ Advisor Datin Norhaini Udin Vice Advisor Dr. Ramle Kasin Editor Dr. Rosmin Kasran Editorial Committee Dr. Alias Awang Dr. Ahmad Kamil Mohd Jaaffar Dr. Douglas Furtek Dr. Fisal Ahmad Dr. Hii Ching Lik Dr. Rozita Osman Dr. Samuel Yap Kian Chee Dr. Tan Chia Lock Dr. Zainal Baharum En. Mohamed Yusof Ishak Hjh. Winoryantie Sulaiman Pn. Harnie Harun Pn. Suzannah Sharif Published by MALAYSIAN COCOA BOARD 5-7th Floor, Wisma SEDCO Lorong Plaza Wawasan, Off Coastal Highway 88999 Kota Kinabalu, Sabah, Malaysia ©All rights reserved. No part of this publication may be reproduced in any form or by any means without permission in writing from Malaysian Cocoa Board CONTENTS ASSESSMENT OF SOMATIC EMBRYOGENESIS POTENTIAL OF ELITE MALAYSIAN Theobroma cacao CLONES 1 Siti Norhana, M. A., Haikal Eman, A., Ahmad Kamil, M. J. and Kasran, R. THE EFFECT OF ASCORBIC ACID IN THE MATURATION OF COCOA SOMATIC EMBRYOS 5 Norasekin, T. and Ducos, J.P. IMPROVEMENTS OF Theobroma cacao ACCLIMATIZATION TO EX VITRO ENVIRONMENT 11 Nik Aziz, N. I., Jasli, M., Misak, E., Abdul Asui, N. and Kasran, R. DEVELOPMENT OF SNP GENOTYPING ASSAYS IN COCOA POD BORER USING REAL-TIME PCR Kasran, R., Roslina, M.S., David, A., Nuraziawati, M.Y., Navies, M.., Mellisa, G., Fahmi, W. and 19 Larry, C. IDENTIFICATION OF THE POTENTIAL RESISTANCE GENES IN Theobroma cacao TO COCOA POD BORER INSECT (Conopomorpha cramerella) IN RELATION TO HOST- PATHOGEN INTERACTION USING RNA-SEQ TECHNOLOGY 40 Roslina, M.S., David, A., Anisah, S., Navies, M., Kasran, R., K., Mellisa, G.,Fahmi, W. -
Tarantulas and Social Spiders
Tarantulas and Social Spiders: A Tale of Sex and Silk by Jonathan Bull BSc (Hons) MSc ICL Thesis Presented to the Institute of Biology of The University of Nottingham in Partial Fulfilment of the Requirements for the Degree of Doctor of Philosophy The University of Nottingham May 2012 DEDICATION To my parents… …because they both said to dedicate it to the other… I dedicate it to both ii ACKNOWLEDGEMENTS First and foremost I would like to thank my supervisor Dr Sara Goodacre for her guidance and support. I am also hugely endebted to Dr Keith Spriggs who became my mentor in the field of RNA and without whom my understanding of the field would have been but a fraction of what it is now. Particular thanks go to Professor John Brookfield, an expert in the field of biological statistics and data retrieval. Likewise with Dr Susan Liddell for her proteomics assistance, a truly remarkable individual on par with Professor Brookfield in being able to simplify even the most complex techniques and analyses. Finally, I would really like to thank Janet Beccaloni for her time and resources at the Natural History Museum, London, permitting me access to the collections therein; ten years on and still a delight. Finally, amongst the greats, Alexander ‘Sasha’ Kondrashov… a true inspiration. I would also like to express my gratitude to those who, although may not have directly contributed, should not be forgotten due to their continued assistance and considerate nature: Dr Chris Wade (five straight hours of help was not uncommon!), Sue Buxton (direct to my bench creepy crawlies), Sheila Keeble (ventures and cleans where others dare not), Alice Young (read/checked my thesis and overcame her arachnophobia!) and all those in the Centre for Biomolecular Sciences. -
Pain Research Product Guide | Edition 2
Pain Research Product Guide | Edition 2 Chili plant Capsicum annuum A source of Capsaicin Contents by Research Area: • Nociception • Ion Channels • G-Protein-Coupled Receptors • Intracellular Signaling Tocris Product Guide Series Pain Research Contents Page Nociception 3 Ion Channels 4 G-Protein-Coupled Receptors 12 Intracellular Signaling 18 List of Acronyms 21 Related Literature 22 Pain Research Products 23 Further Reading 34 Introduction Pain is a major public health problem with studies suggesting one fifth of the general population in both the USA and Europe are affected by long term pain. The International Association for the Study of Pain (IASP) defines pain as ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’. Management of chronic pain in the clinic has seen only limited progress in recent decades. Treatment of pain has been reliant on, and is still dominated by two classical medications: opioids and non-steroidal anti-inflammatory drugs (NSAIDs). However, side effects such as dependence associated with opioids and gastric ulceration associated with NSAIDs demonstrates the need for new drug targets and novel compounds that will bring in a new era of pain therapeutics. Pain has been classified into three major types: nociceptive pain, inflammatory pain and neuropathic or pathological pain. Nociceptive pain involves the transduction of painful stimuli by peripheral sensory nerve fibers called nociceptors. Neuropathic pain results from damage or disease affecting the sensory system, and inflammatory pain represents the immunological response to injury through inflammatory mediators that contribute to pain. Our latest pain research guide focuses on nociception and the transduction of pain to the spinal cord, examining some of the main classical targets as well as emerging pain targets. -
(12) Patent Application Publication (10) Pub. No.: US 2007/0191272 A1 Stemmer Et Al
US 200701.91272A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0191272 A1 Stemmer et al. (43) Pub. Date: Aug. 16, 2007 (54) PROTEINACEOUS PHARMACEUTICALS Publication Classification AND USES THEREOF (76) Inventors: Willem P.C. Stemmer, Los Gatos, CA (51) Int. Cl. (US); Volker Schellenberger, Palo A6II 38/16 (2006.01) Alto, CA (US); Martin Bader, C40B 40/08 (2006.01) Mountain View, CA (US); Michael C40B 40/10 (2006.01) Scholle, Mountain View, CA (US) C07K I4/47 (2006.01) (52) U.S. Cl. ................. 514/12: 435/7.1: 435/6; 530/324 Correspondence Address: WILSON SONSN GOODRCH & ROSAT 650 PAGE MILL ROAD (57) ABSTRACT PALO ALTO, CA 94304-1050 (US) (21) Appl. No.: 11/528,927 The present invention provides cysteine-containing scaf folds and/or proteins, expression vectors, host cell and (22) Filed: Sep. 27, 2006 display systems harboring and/or expressing such cysteine containing products. The present invention also provides Related U.S. Application Data methods of designing libraries of Such products, methods of (60) Provisional application No. 60/721,270, filed on Sep. screening Such libraries to yield entities exhibiting binding 27, 2005. Provisional application No. 60/721,188, specificities towards a target molecule. Further provided by filed on Sep. 27, 2005. Provisional application No. the invention are pharmaceutical compositions comprising 60/743,622, filed on Mar. 21, 2006. the cysteine-containing products of the present invention. Patent Application Publication Aug. 16, 2007 Sheet 1 of 46 US 2007/0191272 A1 Takara togra: Patent Application Publication Aug. 16, 2007 Sheet 2 of 46 US 2007/0191272 A1 FIG. -
Husbandry Manual for Exotic Tarantulas
Husbandry Manual for Exotic Tarantulas Order: Araneae Family: Theraphosidae Author: Nathan Psaila Date: 13 October 2005 Sydney Institute of TAFE, Ultimo Course: Zookeeping Cert. III 5867 Lecturer: Graeme Phipps Table of Contents Introduction 6 1 Taxonomy 7 1.1 Nomenclature 7 1.2 Common Names 7 2 Natural History 9 2.1 Basic Anatomy 10 2.2 Mass & Basic Body Measurements 14 2.3 Sexual Dimorphism 15 2.4 Distribution & Habitat 16 2.5 Conservation Status 17 2.6 Diet in the Wild 17 2.7 Longevity 18 3 Housing Requirements 20 3.1 Exhibit/Holding Area Design 20 3.2 Enclosure Design 21 3.3 Spatial Requirements 22 3.4 Temperature Requirements 22 3.4.1 Temperature Problems 23 3.5 Humidity Requirements 24 3.5.1 Humidity Problems 27 3.6 Substrate 29 3.7 Enclosure Furnishings 30 3.8 Lighting 31 4 General Husbandry 32 4.1 Hygiene and Cleaning 32 4.1.1 Cleaning Procedures 33 2 4.2 Record Keeping 35 4.3 Methods of Identification 35 4.4 Routine Data Collection 36 5 Feeding Requirements 37 5.1 Captive Diet 37 5.2 Supplements 38 5.3 Presentation of Food 38 6 Handling and Transport 41 6.1 Timing of Capture and handling 41 6.2 Catching Equipment 41 6.3 Capture and Restraint Techniques 41 6.4 Weighing and Examination 44 6.5 Transport Requirements 44 6.5.1 Box Design 44 6.5.2 Furnishings 44 6.5.3 Water and Food 45 6.5.4 Release from Box 45 7 Health Requirements 46 7.1 Daily Health Checks 46 7.2 Detailed Physical Examination 47 7.3 Chemical Restraint 47 7.4 Routine Treatments 48 7.5 Known Health Problems 48 7.5.1 Dehydration 48 7.5.2 Punctures and Lesions 48 7.5.3 -
Product Update Price List Winter 2014 / Spring 2015 (£)
Product update Price list winter 2014 / Spring 2015 (£) Say to affordable and trusted life science tools! • Agonists & antagonists • Fluorescent tools • Dyes & stains • Activators & inhibitors • Peptides & proteins • Antibodies hellobio•com Contents G protein coupled receptors 3 Glutamate 3 Group I (mGlu1, mGlu5) receptors 3 Group II (mGlu2, mGlu3) receptors 3 Group I & II receptors 3 Group III (mGlu4, mGlu6, mGlu7, mGlu8) receptors 4 mGlu – non-selective 4 GABAB 4 Adrenoceptors 4 Other receptors 5 Ligand Gated ion channels 5 Ionotropic glutamate receptors 5 NMDA 5 AMPA 6 Kainate 7 Glutamate – non-selective 7 GABAA 7 Voltage-gated ion channels 8 Calcium Channels 8 Potassium Channels 9 Sodium Channels 10 TRP 11 Other Ion channels 12 Transporters 12 GABA 12 Glutamate 12 Other 12 Enzymes 13 Kinase 13 Phosphatase 14 Hydrolase 14 Synthase 14 Other 14 Signaling pathways & processes 15 Proteins 15 Dyes & stains 15 G protein coupled receptors Cat no. Product name Overview Purity Pack sizes and prices Glutamate: Group I (mGlu1, mGlu5) receptors Agonists & activators HB0048 (S)-3-Hydroxyphenylglycine mGlu1 agonist >99% 10mg £112 50mg £447 HB0193 CHPG Sodium salt Water soluble, selective mGlu5 agonist >99% 10mg £59 50mg £237 HB0026 (R,S)-3,5-DHPG Selective mGlu1 / mGlu5 agonist >99% 10mg £70 50mg £282 HB0045 (S)-3,5-DHPG Selective group I mGlu receptor agonist >98% 1mg £42 5mg £83 10mg £124 HB0589 S-Sulfo-L-cysteine sodium salt mGlu1α / mGlu5a agonist 10mg £95 50mg £381 Antagonists HB0049 (S)-4-Carboxyphenylglycine Competitive, selective group 1 -
Araneae (Spider) Photos
Araneae (Spider) Photos Araneae (Spiders) About Information on: Spider Photos of Links to WWW Spiders Spiders of North America Relationships Spider Groups Spider Resources -- An Identification Manual About Spiders As in the other arachnid orders, appendage specialization is very important in the evolution of spiders. In spiders the five pairs of appendages of the prosoma (one of the two main body sections) that follow the chelicerae are the pedipalps followed by four pairs of walking legs. The pedipalps are modified to serve as mating organs by mature male spiders. These modifications are often very complicated and differences in their structure are important characteristics used by araneologists in the classification of spiders. Pedipalps in female spiders are structurally much simpler and are used for sensing, manipulating food and sometimes in locomotion. It is relatively easy to tell mature or nearly mature males from female spiders (at least in most groups) by looking at the pedipalps -- in females they look like functional but small legs while in males the ends tend to be enlarged, often greatly so. In young spiders these differences are not evident. There are also appendages on the opisthosoma (the rear body section, the one with no walking legs) the best known being the spinnerets. In the first spiders there were four pairs of spinnerets. Living spiders may have four e.g., (liphistiomorph spiders) or three pairs (e.g., mygalomorph and ecribellate araneomorphs) or three paris of spinnerets and a silk spinning plate called a cribellum (the earliest and many extant araneomorph spiders). Spinnerets' history as appendages is suggested in part by their being projections away from the opisthosoma and the fact that they may retain muscles for movement Much of the success of spiders traces directly to their extensive use of silk and poison.